Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis

Prior treatment

• Patients who received any vaccine within 4 weeks prior to secukinumab initiation.

Other illness

• Known or suspected severe hypersensitivity for secukinumab, formulation excipients, or injection device components (i.e., latex).
• History of chronic recurrent infection.
• Clinically significant infection exacerbation, including active tuberculosis.
• Active inflammatory bowel disease at inclusion.
• Any medical or psychological condition in the investigator's opinion which may prevent the study participation.

Age

• Age \<6 years or ≥18 years.

Other

• Pregnancy and breastfeeding.
• Patients participating in parallel in an interventional clinical trial.
• Patients participating in parallel in other Novartis-sponsored non-interventional study generating primary data for secukinumab.
• Patients within the safety follow-up phase of interventional study.

• Written informed consent and legal representative's permission for study participation obtained prior to beginning of participation in the study.
• Age ≥6 to \<18 years old.
• Established diagnosis of active moderate-to-severe plaque psoriasis defined as a PASI score ≥ 10, body surface area (BSA) involvement of ≥10% and PGA score ≥ 3 only or with concomitant psoriatic arthritis.
• Failure or intolerance of prior psoriasis treatment.
• Patient was prescribed with secukinumab within 4-16 weeks before inclusion.
• Decision for secukinumab prescription was made by the attending physician according to the approved national label during routine clinical practice, regardless of this non-interventional study conduct.